MX2023007583A - Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. - Google Patents
Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.Info
- Publication number
- MX2023007583A MX2023007583A MX2023007583A MX2023007583A MX2023007583A MX 2023007583 A MX2023007583 A MX 2023007583A MX 2023007583 A MX2023007583 A MX 2023007583A MX 2023007583 A MX2023007583 A MX 2023007583A MX 2023007583 A MX2023007583 A MX 2023007583A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- methods
- antibodies
- transmembrane proteins
- produce
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130044P | 2020-12-23 | 2020-12-23 | |
| PCT/US2021/064769 WO2022140494A1 (en) | 2020-12-23 | 2021-12-22 | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007583A true MX2023007583A (es) | 2023-07-07 |
Family
ID=82022075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007583A MX2023007583A (es) | 2020-12-23 | 2021-12-22 | Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12371487B2 (https=) |
| EP (1) | EP4267608A1 (https=) |
| JP (1) | JP2024501796A (https=) |
| KR (1) | KR20230124594A (https=) |
| CN (1) | CN116635413A (https=) |
| AU (1) | AU2021409906A1 (https=) |
| BR (1) | BR112023011689A2 (https=) |
| CA (1) | CA3197426A1 (https=) |
| IL (1) | IL303865A (https=) |
| MX (1) | MX2023007583A (https=) |
| TW (1) | TW202242114A (https=) |
| WO (1) | WO2022140494A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116622754A (zh) * | 2023-05-31 | 2023-08-22 | 南开大学 | 一种定点标记的跨膜蛋白纳米盘及其制备方法和应用 |
| CN118027202B (zh) * | 2024-03-14 | 2024-08-13 | 恺佧生物科技(上海)有限公司 | 结合slc13a5膜蛋白的抗体 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK1345959T3 (da) | 2000-11-20 | 2011-09-05 | Univ Illinois | Membranscaffoldproteiner |
| JP4939926B2 (ja) | 2003-02-14 | 2012-05-30 | アノシス・インコーポレーテッド | 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド |
| WO2006058890A2 (en) * | 2004-11-30 | 2006-06-08 | Novo Nordisk A/S | Method of producing antibodies |
| EP1910513B1 (en) * | 2005-07-01 | 2016-08-10 | John Schrader | Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells. |
| EP2121007A1 (en) | 2006-12-21 | 2009-11-25 | Cytos Biotechnology AG | Circular ccr5 peptide conjugates and uses thereof |
| GB2456236B8 (en) | 2007-03-22 | 2009-12-09 | Heptares Therapeutics Ltd | Stable muscarinic receptor mutants |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| PT3034608T (pt) | 2010-06-22 | 2019-05-28 | Regeneron Pharma | Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana |
| ME02106B (me) | 2011-02-25 | 2015-10-20 | Regeneron Pharma | Miševi sa adam6 |
| EP2617732A1 (en) | 2012-01-19 | 2013-07-24 | Vib Vzw | Tools and methods for expression of membrane proteins |
| MX353278B (es) | 2012-03-06 | 2018-01-05 | Regeneron Pharma | Raton con cadena ligera comun. |
| ES2676827T3 (es) | 2012-06-01 | 2018-07-25 | Heptares Therapeutics Limited | Ensayos |
| MX2014014891A (es) | 2012-06-05 | 2015-06-17 | Regeneron Pharma | Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun. |
| EP2745834B1 (en) | 2012-12-18 | 2016-09-28 | Jens Frauenfeld | Salipro particles |
| HK1218550A1 (zh) | 2013-03-13 | 2017-02-24 | Regeneron Pharmaceuticals, Inc. | 常見輕鏈小鼠 |
| EP4545567A3 (en) | 2013-03-13 | 2025-08-13 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US9850303B2 (en) | 2013-03-15 | 2017-12-26 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to tetraspanin 8 |
| ES2939555T3 (es) * | 2014-11-14 | 2023-04-24 | Regeneron Pharma | Método para generar anticuerpos de alta afinidad |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| EP3284460A1 (en) | 2016-08-19 | 2018-02-21 | Salipro Biotech AG | Saposin lipoprotein particles and libraries from crude membranes |
| SG10201913483XA (en) | 2016-11-04 | 2020-03-30 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| HUE060608T2 (hu) | 2017-12-05 | 2023-03-28 | Regeneron Pharma | Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása |
| US20210214719A1 (en) | 2018-05-31 | 2021-07-15 | Kangti Pte. Ltd. | A yeast phenotypic screening method for isolation of functional antibodies against g-protein coupled receptors |
| US20210299070A1 (en) | 2018-09-21 | 2021-09-30 | Jnana Therapeutics, Inc. | Methods of treating creatine transporter deficiency |
| US20210371403A1 (en) | 2018-09-21 | 2021-12-02 | Jnana Therapeutics, Inc. | Small molecules targeting mutant mammalian proteins |
| WO2020061476A1 (en) | 2018-09-21 | 2020-03-26 | Jnana Therapeutics, Inc. | Small molecules targeting mutant mammalian proteins |
-
2021
- 2021-12-22 IL IL303865A patent/IL303865A/en unknown
- 2021-12-22 KR KR1020237021168A patent/KR20230124594A/ko active Pending
- 2021-12-22 CA CA3197426A patent/CA3197426A1/en active Pending
- 2021-12-22 CN CN202180086859.7A patent/CN116635413A/zh active Pending
- 2021-12-22 US US17/558,645 patent/US12371487B2/en active Active
- 2021-12-22 AU AU2021409906A patent/AU2021409906A1/en active Pending
- 2021-12-22 BR BR112023011689A patent/BR112023011689A2/pt unknown
- 2021-12-22 MX MX2023007583A patent/MX2023007583A/es unknown
- 2021-12-22 TW TW110148096A patent/TW202242114A/zh unknown
- 2021-12-22 JP JP2023536468A patent/JP2024501796A/ja active Pending
- 2021-12-22 EP EP21847855.0A patent/EP4267608A1/en active Pending
- 2021-12-22 WO PCT/US2021/064769 patent/WO2022140494A1/en not_active Ceased
-
2025
- 2025-06-20 US US19/243,816 patent/US20250313624A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220195038A1 (en) | 2022-06-23 |
| JP2024501796A (ja) | 2024-01-16 |
| EP4267608A1 (en) | 2023-11-01 |
| AU2021409906A9 (en) | 2024-10-10 |
| US20250313624A1 (en) | 2025-10-09 |
| AU2021409906A1 (en) | 2023-06-15 |
| BR112023011689A2 (pt) | 2023-10-31 |
| WO2022140494A1 (en) | 2022-06-30 |
| KR20230124594A (ko) | 2023-08-25 |
| TW202242114A (zh) | 2022-11-01 |
| CN116635413A (zh) | 2023-08-22 |
| CA3197426A1 (en) | 2022-06-30 |
| IL303865A (en) | 2023-08-01 |
| US12371487B2 (en) | 2025-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| PH12021500051A1 (en) | Cd3 antigen binding fragments and compositions comprising same | |
| CR20200014A (es) | Molécula de polipéptido con especificidad dual mejorada | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| EP4483895A3 (en) | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom | |
| UY38803A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas | |
| SA523441343B1 (ar) | Il-4r وil-31 أجسام مضادة متعددة الخصوصية ذات خصوصية تجاه | |
| EP4249511A3 (en) | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
| AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| WO2022032004A3 (en) | Anti-claudin 18.2 multi-specific antibodies and uses thereof | |
| MY210018A (en) | Monoclonal antibody that binds specifically to gitr | |
| PH12022552520A1 (en) | Antibodies binding siglec15 and uses thereof | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| MX2023007583A (es) | Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. | |
| MX2022003432A (es) | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| MX2024015072A (es) | Anticuerpos anti-egfr/met y usos de los mismos | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| WO2021112676A3 (en) | Methods and means for attracting immune effector cells to tumor cells | |
| ZA202408388B (en) | Antibodies targeting sirp-alpha and uses thereof | |
| MX2024006969A (es) | Anticuerpos dlk1 y metodos de tratamiento del cancer. | |
| WO2019116089A3 (en) | A method of producing a vaccine composition and uses thereof | |
| WO2022081443A3 (en) | Anti-psma antibodies and uses thereof | |
| MX2023009568A (es) | Materiales y métodos para el direccionamiento mejorado de enlazador. |